Nasdaq-listed Zentalis Pharmaceuticals has appointed Andrea Paul as general counsel and corporate secretary, effective August 1.
Paul will join Zentalis from LogicBio Therapeutics, where she has been general counsel and corporate secretary since May 2021. She previously held positions of increasing responsibility at Akebia Therapeutics, most recently as vice president for legal. During her time at Akebia, Paul played a key legal role in the company’s merger with Keryx Biopharmaceuticals, in addition to the company’s financing and business development transactions.
Before that, Paul was senior corporate counsel at Momenta Pharmaceuticals. She began her legal career as an associate at law firms Mintz Levin Cohn Ferris Glovsky and Popeo and Sullivan & Cromwell.
Zentalis is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting cancers.
CEO Dr Kimberly Blackwell says in a statement: ‘I am delighted to welcome Andrea to our team. Her extensive expertise in managing complex legal and compliance matters will offer invaluable perspective as we drive forward our clinical plans. I am confident she will excel in her role of leading our legal division to achieve our near and long-term milestones.’
Ben Maiden
Ben Maiden is the editor-at-large of Governance Intelligence, an IR Media publication, having joined the company in December 2016. He is based in New York. Ben was previously managing editor of Compliance Reporter, covering regulatory and compliance...
